Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study

Annals of the Rheumatic Diseases

Volumn 71, Issue 4, 2012, Pages 541-548

  Baranauskaite, Asta ^a   Raffayová, Helena ^b   Kungurov, N V ^c   Kubanova, Anna ^d   Venalis, Algirdas ^e   Helmle, Laszlo ^f   Srinivasan, Shankar ^g   Nasonov, Evgeny ^h   Vastesaeger, Nathan ⁱ   Nasyrova, R ^h   Parsik, E ^j   Otsa, K ^k   Butrimiene, I ^e   Pileckyte, M ^a   Tlustochowicz, W ^l   Kucharz, E ^m   Szekanecz, Z ⁿ   Poor, G ^o   Koo, E ^p   Hodinka, L ^o   Macejova, Z ^q   Direskeneli, H ^r   Akkoc, N ^s   Kabasakal, Y ^t   Ertenli, I ^u   Khatib, F ^v   Van Duuren, E M ^w   Spargo, C ^x   Louw, I ^y   Codreanu, C ^z   Ionescu, R ^aa   Chireac, R M ^ab   Rednic, S ^ac   Hammoudeh, M ^ad   Szechinski, J ^ae   Rell Bakalarska, M ^af   Avraham, D ^ag   Andersone, D ^ah   Keszthelyi, P ^ai   Suranyi, P ^aj   more..

^a KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^b National Institute for Rheumatology Diseases   (Slovakia)

^c Urals Dermatovenereology Institute   (Russian Federation)

^d Central DermatoVenereology Institute   (Russian Federation)

^e VILNIUS UNIVERSITY   (Lithuania)

^f MSD   (Hungary)

^g MERCK RESEARCH LABORATORIES   (United States)

^h V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

ⁱ MSD   (Belgium)

^j North Estonian Regional Hospital   (Estonia)

^k East Tallinn Central Hospital   (Estonia)

^l Centralny Szpital Kliniczny   (Poland)

^m Samodzielny Publiczny Szpital   (Poland)

ⁿ UNIVERSITY OF DEBRECEN   (Hungary)

^o NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^p Department of Internal Medicine   (Hungary)

^q FACULTY HOSPITAL   (Slovakia)

^r MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^s DOKUZ EYLUL UNIVERSITY   (Turkey)

^t EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^u HACETTEPE UNIVERSITY   (Turkey)

^v Arwyp Medical Suites   (South Africa)

^w Jacaranda Hospital   (South Africa)

^x Vincent Pallotti Hospital   (South Africa)

^y Panorama Medi Clinic   (South Africa)

^z Sf Maria Clinical Hospital   (Romania)

^aa Sp Clinic de Recuperare   (Romania)

^ab Spitalul Judetean Cluj   (Romania)

^ac HAMAD MEDICAL CORPORATION   (Qatar)

^ad Prywatny Gabinet Internistyczno Reumatologiczny   (Poland)

^ae Przychodnia Przykliniczna   (Poland)

^af Meir MC Dermatology   (Israel)

^ag PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^ah Pandy Kalman Bekes County Hospital   (Hungary)

^ai Centrul de Boli   (Romania)

^aj Kenezy Korhaz Rendelointezet   (Hungary)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DEXAMETHASONE; INFLIXIMAB; METHOTREXATE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMERICAN COLLEGE OF RHEUMATOLOGY 20; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DACTYLITIS; DIARRHEA; DISEASE ACTIVITY SCORE IN 28 JOINT; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENTHESITIS; ERYTHEMA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; HUMAN; INFORMED CONSENT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

EID: 85027926210     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.152223     Document Type: Article

References (29)

1. Gladman DD. Psoriatic arthritis from Wright's era until today. J Rheumatol Suppl 2009;83:4-8.
2. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96. (Pubitemid 26249398)
3. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50. (Pubitemid 30262512)
4. Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002;29:2577-82. (Pubitemid 35416965)
5. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12. (Pubitemid 20213507)
6. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
7. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008;26 (5 Suppl 51):S62-5.
8. Borman P, Toy GG, Babaoglu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 2007;26:330-4. (Pubitemid 46486962)
9. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36. (Pubitemid 44352553)
10. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. (Pubitemid 351509657)
11. Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22:40-55.
12. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
13. Black RL, O'Brien WM, Vanscott EJ, et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964;189:743-7.
14. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81. (Pubitemid 14134777)
15. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
16. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of a randomized, placebocontrolled study. Arthritis Rheum 2009;60:976-86.
17. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
18. Mease P, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;52:3279-89.
19. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
20. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
21. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7. (Pubitemid 41113349)
22. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
23. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43. (Pubitemid 44133266)
24. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505. (Pubitemid 46580471)
25. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
26. Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. Chichester: Wiley, 2002.
27. Myers WR. Handling missing data in clinical trials: an overview. Drug Information J 2000;34:525-33. (Pubitemid 30351005)
28. Dmitrienko A, Molenberghs G, Chuang-Stein C, et al. Analysis of Clinical Trials Using SAS: A Practical Guide. Cary, NC: SAS Institute Inc, 2005.
29. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2011; Published Online First: 27 September 2011. doi:10.1136/annrheumdis-2011-200350.